title: [Effect of the treatment with amlodipine on left ventricular hypertrophy in hypertensive patients].
abstract: BACKGROUND
  Left ventricular hypertrophy (LVH) is one of the physiopathological effects of hypertension and one of the main risk factors for sudden death, myocardial infarction and congestive heart failure. Drugs to treat hypertension must not only reduce blood pressure, but also modify the facts which lead to ventricular hypertrophy. This study has been designed to assess the effect of amlodipine, a calcium-antagonist, on LVH in hypertensive patients.
  
  
  METHODS
  20 hypertensive patients (mild to moderate, both sexes, mean age 45.0 yr) were included in a single-blind study. After an initial, four weeks placebo period, active treatment was given (amlodipine 5 mg a day). Dose titration was made after 4-8 weeks to 10 mg a day if necessary and continued until the end of the study. Systolic (SBP) and diastolic blood pressure (DBP), as well as pulse rate (PR) and adverse events were recorded at every visit. Blood and urine analysis, catecholamine, plasmatic renin activity and Mode M echocardiography were made at the beginning and the end of the study.
  
  
  RESULTS
  Only one patient was excluded. SBP and DBP showed a significantly fall (p < 0.001). In 80% of patients DBP fell under 90 mm Hg. Every echocardiographic parameter, but left ventricular diastolic dimension, showed significantly reductions at the end of the study: septum thickness (p = 0.001), posterior wall thickness (p = 0.001), left ventricular systolic dimension (p = 0.014), wall relative thickness (p = 0.015), shortening fraction (p = 0.009), left ventricular mass (p = 0.001) and corrected left ventricular mass (p = 0.001). Blood parameters did not modify.
  
  
  CONCLUSIONS
  Amlodipine has a beneficial effect on LVH and also is an effective and safe drug to treat mild to moderate hypertension.
authors.affiliation: Departamento de Medicina, Unidad de Hipertensión Arterial y Factores de Riesgo, Hospital Universitario Virgen Macarena, Sevilla.
authors.forename: J
authors.initials: J
authors.lastname: Oliván
authors.forename: R
authors.initials: R
authors.lastname: Moreno
authors.forename: M
authors.initials: M
authors.lastname: Hoyos
authors.forename: E
authors.initials: E
authors.lastname: Ramos
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez
authors.forename: J L
authors.initials: JL
authors.lastname: Pizarro
authors.forename: E
authors.initials: E
authors.lastname: Justo
authors.forename: R
authors.initials: R
authors.lastname: Pérez Cano
mesh_terms: D017311:Amlodipine / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004452:Echocardiography; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method
chemical_list: D000959:Antihypertensive Agents; D017311:Amlodipine